Argenx buys a peptide discovery engine to widen its immunology playbook
Argenx is moving beyond antibodies and into oral peptide drug discovery with its $550 million upfront acquisition of Unnatural Products, a Santa Cruz startup built around macrocyclic peptides. The transaction gives the Amsterdam-based company a second therapeutic modality at a time when competition in immunology is shifting toward medicines that are easier to take and, in some cases, easier to scale commercially.
The logic of the deal is straightforward. Antibodies have powered Argenx’s rise in rare autoimmune disease, but they remain injectable products. Oral peptides offer a different engineering problem and a different clinical value proposition: preserve biologic activity while surviving the digestive tract and crossing the intestinal barrier. UNP’s ring-shaped macrocyclic peptides are designed to do exactly that, shielding amino acids from digestive enzymes and improving passage through gut tissue.
The acquisition also reflects a broader push in biopharma toward oral peptide medicines for immune-mediated disease. Several large drug makers have already staked claims in the category, and Argenx is now joining that race with a platform that could widen its target reach beyond the antibody-centric programs that made Vyvgart the company’s flagship.
Why macrocyclic peptides matter in immunology
Peptides are attractive drug scaffolds because they can be highly selective and can interact with disease targets that may be difficult to address with small molecules or conventional biologics. Their weakness has always been pharmacokinetic: linear peptides are rapidly degraded in the gut and generally do not move easily across intestinal membranes. Injectable delivery has therefore been the default for many peptide therapeutics.
Macrocyclization changes that equation. By locking the molecule into a ring, the chemistry can reduce exposure of vulnerable peptide bonds to enzymatic breakdown and can stabilize conformations that favor transport. The result is a platform that may support oral dosing while preserving enough structural precision to engage difficult targets. In immunology, where chronic treatment is often required, an oral option can alter adherence, patient preference, and treatment sequencing even before any efficacy advantage is proven.
For Argenx, the strategic appeal is not simply convenience. It is modality optionality. The company has built its commercial identity around engineered antibody fragments, but oral peptides could open a path to biologic-like selectivity without requiring repeated injections or infusions. In a field crowded with injectable agents, that distinction can shape how a future therapy is positioned in the clinic.
The deal extends a collaboration already in motion
Argenx and Unnatural Products had already been working together for more than a year before the buyout. The companies had not disclosed the progress of the research, and they did not identify the underlying targets beyond describing them as historically “undruggable” disease targets. Even so, Argenx was persuaded enough by the platform to acquire the startup outright and retain its team and California site as the company’s peptide discovery hub.
The financial structure leaves room for more value if the science advances. UNP could receive up to $595 million in milestone payments depending on the progress of the programs. Argenx had also made an equity investment in the startup before the acquisition, a sign that the relationship was already moving from exploratory collaboration toward deeper strategic alignment.
Argenx has been disciplined in how it expands. Karen Massey framed the move as an investment “where it will count the most for patients.” That statement fits the company’s recent pattern: build around core expertise, then add adjacent technologies only when they expand the ability to reach new biology or new disease settings.
A company with commercial momentum and unfinished business
Vyvgart remains the centerpiece of Argenx’s immunology business. The therapy, available as an infusion and a subcutaneous formulation, has FDA approvals for two rare inflammatory disorders affecting muscles and nerves. The company reported $4.5 billion in product sales in the first nine months of 2026, a 58.1% increase from the same period a year earlier. Those numbers give Argenx both the capital and the confidence to invest in longer-range discovery bets.
Still, the current portfolio shows both promise and vulnerability. The injectable Vyvgart Hytrulo met the main goals of a Phase 3 study in autoimmune myositis, with results set for presentation at the American College of Rheumatology conference. A month earlier, the company discontinued development of Vyvgart Hytrulo in Sjögren’s disease after a Phase 3 failure in a disorder that causes dry eyes and dry mouth. The contrast is sharp: one program advancing, one shutting down, and a new modality being added in parallel.
The pattern matters because immunology is not a single market. Disease biology varies widely across systemic autoimmune conditions, and success in one indication does not guarantee success in another. Oral peptides may help Argenx reach new targets, but they do not erase the basic development risk that has already appeared in its pipeline.
Oral peptide competition is accelerating
The acquisition lands in a year when oral peptides have become one of the more active corners of biopharma dealmaking. Johnson & Johnson won FDA approval for Icotyde in plaque psoriasis in March. Merck later secured approval for Lipfendra, its cholesterol-lowering macrocyclic peptide. Gilead also agreed to pay nearly $1.3 billion upfront for PepStar Therapeutics, an early-stage macrocyclic peptide program with potential applications in inflammatory bowel disease and beyond.
Argenx is clearly watching the same trend line. Leerink Partners analyst Thomas Smith described the transaction as a way for the company to expand beyond specialized antibodies and add more modality optionality through macrocyclic peptides. In practical terms, that means Argenx is not just buying a startup. It is buying a second molecular language for a company that has already proven it can turn immunology assets into commercial products.
The remaining question is how quickly UNP’s platform can be translated into clinical candidates that justify the price. The startup had raised about $83 million in total, including a $45 million Series B in March, and had said it would use that financing to move closer to the clinic with macrocyclic peptides for cardiometabolic, inflammatory, and immunological disorders. Argenx now inherits that work, along with the challenge of converting a discovery engine into a pipeline with human data.
For now, the transaction is scheduled to close by the end of this year. The science behind it is promising, but the clinical proof still has to arrive.